Work

A Phase 1 Study of Parsaclisib in Combination with Investigator Choice of Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma (CITADEL-112): Preliminary Safety Results

Year: 2022

Type: article

Source: Transplantation and Cellular Therapy

DOI: 10.1016/s2666-6367(22)00685-6

Authors: Juan-Manuel Sancho, Armando Lopez-Guillermo, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Wanying Zhao, Erica Rappold, Peter Langmuir, Martha Mims

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W4220927442

FWCI:

Cites:

Cited by:

Related to: 10